Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Chen, Jinyun

Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. [electronic resource] - Annals of surgical oncology Feb 2009 - 431-9 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1534-4681

10.1245/s10434-008-0220-8 doi


Adenocarcinoma--genetics
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Pancreatic Ductal--genetics
Chemotherapy, Adjuvant
Cisplatin--administration & dosage
Combined Modality Therapy
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p27--genetics
DNA-Binding Proteins--genetics
Deoxycytidine--administration & dosage
Disease Progression
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Proteins--genetics
Nuclear Proteins--genetics
Pancreatic Neoplasms--genetics
Pancreaticoduodenectomy
Polymorphism, Single Nucleotide--genetics
Prognosis
Proto-Oncogene Proteins c-mdm2--genetics
Radiotherapy, Adjuvant
Survival Rate
Time Factors
Tumor Protein p73
Tumor Suppressor Proteins--genetics
Gemcitabine